Morgan Stanley raises Neurocrine Biosciences target price to $191 from $185
NBIX•Morgan Stanley raised its target price for Neurocrine Biosciences to $191 from $185.
Related News
Brazil's CSN swings to Q3 loss as iron ore prices, freight costs bite
SID•
EMA's CHMP recommends indication extensions for Bexsero and Talzenna
PFE•
Morgan Stanley cuts Corteva target price to $13 from $18
CTVA•
Woori Financial Group to attend Morgan Stanley Asia Pacific Summit
WF•
India's October trade deficit hits one-year high of $39.88 billion as gold imports jump
INDA•